

Special Issue

Immune Responses to SARS-CoV-2 Infection and Vaccination

Message from the Guest Editor

The COVID-19 pandemic has caused unprecedented health crises and economic losses worldwide. The SARS-CoV-2 variants evolved with escape mutations and have led to the occurrence of several COVID-19 surge peaks in the past. While the virus continues to evolve with escape mutations, understanding the immune response and antigen recognition to SARS-CoV-2 variants are urgently needed for next-generation vaccine design. This Special Issue aims to understand viral entry mechanisms, immune responses, and antigen recognition in the context of SARS-CoV-2 variants and how broad-spectrum immunity can be archived with current knowledge. We are hoping this Special Issue provides information on developing antibody therapeutics and next-generation vaccine design. We are pleased to invite you to present your latest research, perspectives, communications, and reviews to this Special Issue. All immune-related themes regarding SARS-CoV-2 and other related coronaviruses will be considered. However, we are particularly interested in understanding adaptive immune responses to SARS-CoV-2 infection, vaccination, and other related coronaviruses.

Guest Editor

Dr. Hejun Liu

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

Deadline for manuscript submissions

closed (10 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/117233

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).